SNY

Sanofi ADR

42.30

Sep 22 • 4:28 AM ET -0.20 (-0.47%)

Healthcare Drug Manufacturers - General France Large NASD

Peers: AZN NVS GSK JNJ LLY MRK PFE ABBV BMY NVO

| Held by: FENI PPH FVD AVDE PID GMOI BASV BUSA IDVZ FLV

Index	-
Market Cap	100.82B
Enterprise Value	120.93B
Income	4.69B
Sales	53.47B
Book/sh	32.59
Cash/sh	3.05
Dividend Est.	2.45 (5.79%)
Dividend TTM	2.42 (5.72%)
Dividend Ex-Date	May 04, 2026
Dividend Gr. 3/5Y	8.45% 5.14%
Payout	73.36%
Employees	76493
IPO	Jul 01, 2002

P/E	21.79
Forward P/E	7.99
PEG	1.12
P/S	1.89
P/B	1.30
P/C	13.89
P/FCF	8.36
EV/EBITDA	5.38
EV/Sales	2.26
Quick Ratio	0.64
Current Ratio	0.99
Debt/Eq	0.34
LT Debt/Eq	0.24
Option/Short	Yes / Yes

EPS (ttm)	1.94
EPS next Y	5.29
EPS next Q	1.61
EPS this Y	6.38%
EPS next Y	6.50%
EPS next 5Y	7.15%
EPS past 3/5Y	-11.86% -15.52%
Sales past 3/5Y	2.90% 3.69%
EPS Y/Y TTM	-30.90%
Sales Y/Y TTM	23.68%
EPS Q/Q	-32.22%
Sales Q/Q	18.71%
Earnings	Jul 30 BMO
EPS/Sales Surpr.	3.11% 3.35%

Insider Own	0.00%
Insider Trans	-
Inst Own	7.99%
Inst Trans	-0.10%
ROA	3.12%
ROE	5.70%
ROIC	4.80%
Gross Margin	66.29%
Oper. Margin	27.17%
Profit Margin	8.78%
SMA20	-3.10%
SMA50	-3.53%
SMA200	-6.73%
Trades

Shs Outstand	2.43B
Shs Float	2.38B
Short Float	0.35%
Short Ratio	2.61
Short Interest	8.24M
52W High	52.68 -19.70%
52W Low	40.89 3.45%
Volatility	1.00% 1.26%
ATR (14)	0.67
RSI (14)	38.23
Beta	0.30
Rel Volume	0.00
Avg Volume	3.16M
Volume	580

Perf Week	-0.24%
Perf Month	-7.74%
Perf Quarter	1.68%
Perf Half Y	-5.52%
Perf YTD	-12.71%
Perf Year	-10.02%
Perf 3Y	-21.70%
Perf 5Y	-12.28%
Perf 10Y	10.26%
Recom	2.12
Target Price	50.00
Prev Close	42.50
Price	42.30
Change %	-0.47%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-09-26	Initiated	RBC Capital Mkts	Sector Perform
May-01-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-20-26	Downgrade	BNP Paribas Exane	Outperform → Neutral	$50
Feb-12-26	Downgrade	BofA Securities	Buy → Neutral
Jan-27-26	Initiated	Citigroup	Neutral
Jan-16-26	Downgrade	UBS	Buy → Neutral
Jan-06-26	Downgrade	Barclays	Overweight → Equal Weight
Dec-09-25	Downgrade	Guggenheim	Buy → Neutral
Dec-08-25	Downgrade	JP Morgan	Overweight → Neutral
Sep-08-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$58
Sep-02-25	Upgrade	Deutsche Bank	Hold → Buy
Aug-08-25	Upgrade	JP Morgan	Neutral → Overweight
Apr-15-25	Initiated	Exane BNP Paribas	Outperform	$65
Mar-21-25	Initiated	Goldman	Neutral	$65
Jan-30-25	Upgrade	Deutsche Bank	Sell → Hold
Jul-26-24	Reiterated	Argus	Buy	$55 → $60
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight	$55
Jan-16-24	Resumed	UBS	Buy
Dec-05-23	Downgrade	JP Morgan	Overweight → Neutral
Oct-30-23	Downgrade	Stifel	Buy → Hold

Show Previous Ratings

Sep-19-26 10:30PM	What does the EU have that the U.S. does not? (Investing.com)
Sep-15-26 06:08AM	Cheplapharm to take over 20 medicines and three sites from Sanofi (Pharmaceutical Business Review)
Sep-10-26 09:05AM	Sanofi partners with USA Pickleball to launch "Serve Up Protection" campaign to help protect older adults from COVID-19 with NUVAXOVID (PR Newswire)
Sep-08-26 08:00AM	Sanofi and Keke Palmer team up to urge parents to help protect babies from serious RSV with BEYFORTUS (PR Newswire)
Sep-04-26 06:10AM	GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says (Proactive)
08:33AM	Loading…
Sep-02-26 08:33AM	Novartis stock rises after MS drug remibrutinib trial results (Quartz)
Sep-01-26 07:34AM	Why Novartis Stock Is Heading for Its Best Day Since 2023 After 3 Patient Deaths (Barrons.com)
Aug-28-26 06:34PM	NVAX Stock Climbs As Partnership Model Keeps COVID Vaccine Cash Flow Open (Stocktwits)
04:22PM	Top Stock Reports for NVIDIA, ExxonMobil & HSBC (Zacks)
Aug-27-26 07:25AM	Pharmas new CEOs to watch (Pharma Voice)
Aug-19-26 06:30AM	HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation (TMX Newsfile)
Aug-13-26 06:30AM	Big Tech Drives Up Credit Risk for Safe Firms With No AI Links (Bloomberg)
Aug-06-26 07:19PM	Novavax Inc (NVAX) (Q2 2026) Earnings Call Highlights: Matrix-M Momentum Drives Revenue ... (GuruFocus.com)
05:29PM	NVAX Stock Holds Steady As Novavax Lifts Revenue Outlook On Licensing Pivot Retail Eyes Buyout, More Partnership Deals (Stocktwits)
09:54AM	Novavax tops forecasts and raises revenue outlook as Sanofi collaboration progresses (InvestorsHub)
09:01PM	Loading…
Aug-05-26 09:01PM	Euroapi SA (EAPIF) (H1 2026) Earnings Call Highlights: Transformation Costs and Market ... (GuruFocus.com)
01:05AM	Arrowhead Pharmaceuticals Inc (ARWR) (Q3 2026) Earnings Call Highlights: Strong Phase III Data ... (GuruFocus.com)
Aug-03-26 09:08AM	Medicus Pharma CMO to lead Antev's Teverelix clinical programme (Proactive)
Jul-31-26 07:06AM	Sanofi to rebuild trust with Regeneron; Apnimed adds to string of upsized biotech IPOs (BioPharma Dive)
Jul-30-26 05:04PM	Regeneron Pharmaceuticals Inc (REGN) (Q2 2026) Earnings Call Highlights: Record Dupixent Sales ... (GuruFocus.com)
03:03PM	Sanofi SA (SNY) (Q2 2026) Earnings Call Highlights: Strong Sales Growth and Upgraded Guidance ... (GuruFocus.com)
10:00AM	Regeneron Beats Second-Quarter Expectations as Dupixent Growth Fuels Strong Results (InvestorsHub)
07:59AM	Regeneron beats quarterly estimates on eczema drug strength, shares rise (Reuters)
05:12AM	How Telix landed a $2.1 billion radiopharma deal with Regeneron (Pharma Voice)
Jul-28-26 05:48AM	Kalshi is expanding online betting in drug R&D unless detractors can stop it (Pharma Voice)
Jul-24-26 02:45PM	Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPO (GuruFocus.com)
11:53AM	Eli Lilly-Backed Scribe Therapeutics Jumps 67% After Upsized IPO (Bloomberg)
10:20AM	Sanofi abandons eczema drug approval efforts in another blow to OX40 class (Pharmaceutical Technology)
08:53AM	Sanofi is scrapping its once-touted eczema drug in a new CEO pipeline overhaul (Quartz)
07:35AM	Sanofi halts development of troubled immune drug in eczema (BioPharma Dive)
04:00PM	Loading…
Jul-20-26 04:00PM	Scribe Therapeutics Files $107.2 Million IPO as Sanofi Backs Share Purchase (GuruFocus.com)
Jul-17-26 06:07AM	Arbutus, Sanofi escalate mRNA patent fights; InnoCares TYK2 contender advances (BioPharma Dive)
Jul-16-26 08:00AM	Kalshi Will Offer Sports-Style Betting on Drug Trial Results (Bloomberg)
Jun-30-26 06:53AM	Talawar Therapeutics to debut on Nasdaq with $285m as Dupixent challenger (Pharmaceutical Technology)
Jun-26-26 01:38PM	Sanofi Faces EU Probe With Fines Possibly Reaching 10% (GuruFocus.com)
06:46AM	EU hits France's Sanofi with flu vaccine antitrust probe (AFP)
Jun-25-26 09:00AM	REPLAY: Fireside Chat with NanoViricides President & Exec. Chairman Anil R. Diwan (IPO-Edge.com)
Jun-24-26 04:12AM	Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor (BioPharma Dive)
Jun-23-26 06:21AM	How Kardigan spun deal leftovers into a $400M IPO (BioPharma Dive)
Jun-22-26 02:59PM	AbbVie's $10.9 Billion Apogee Deal Joins a $200 Billion Pharma Spree (GuruFocus.com)
07:12AM	Sanofi swaps R&D leaders; Mercks Prometheus deal pays dividends (BioPharma Dive)
05:21AM	Backed by Sanofi and Roche, Orano Med chases radiopharma leadership (Pharma Voice)
05:05AM	Japan approves Sanofi's Sarclisa combo for MM treatment (Pharmaceutical Business Review)
03:00AM	Bionyra brings in $165M for next-generation immune drugs (BioPharma Dive)
Jun-18-26 08:56PM	How One Partnership Profit Line Reframes The Regeneron Pharmaceuticals Stock Story (Trefis)
Jun-12-26 05:13PM	DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results (Stocktwits)
Jun-11-26 12:21PM	Drug developers eye sports biggest stage as World Cup fever builds (Pharmaceutical Technology)
Jun-10-26 07:28AM	Sanofi stops immune drug trial in latest research setback (BioPharma Dive)
05:48AM	Sanofi Halts Phase 3 CIDP Trial for Riliprubart Following Interim Review (SAN) (InvestorsHub)
Jun-08-26 06:05AM	Sanofi and Owkin partner to develop next-generation biopharma AI agents (Pharmaceutical Business Review)
Jun-01-26 07:17AM	MIT bullish on its Initiative for New Manufacturing at the one-year mark (Manufacturing Dive)
May-29-26 06:06AM	FDA grants priority review for Sanofi's venglustat NDA (Pharmaceutical Business Review)
May-20-26 01:54PM	ATS 2026: Mixed results for Sanofi/Regenerons itepekimab cloud COPD prospects (Clinical Trials Arena)
May-18-26 07:28AM	Regeneron Stock Sinks as Key Melanoma Drug Trial Fails to Beat Merck's Keytruda (Barrons.com)
May-15-26 06:29AM	Sanofis vaccine bump; the new FDA commish (Pharma Voice)
May-06-26 04:50PM	Novavax, Inc. Q1 2026 Earnings Call Summary (Moby)
12:42PM	Sanofi Supports AlphaDetect to Accelerate Detection of Alpha-1 (PR Newswire)
May-05-26 10:14AM	Regeneron (REGN) Dupixent Phase 4 Trial Results Show Improved Esophageal Function in EoE (InvestorsHub)
Apr-30-26 05:24AM	Regeneron Q1 2026 net income falls 10% to $727m (Pharmaceutical Technology)
Apr-29-26 10:12AM	Regeneron shares slide despite Q1 beat (Proactive)
08:53AM	Regeneron Tops Q1 Estimates on Dupixent Momentum (InvestorsHub)
07:15AM	Regeneron beats first quarter estimates on Dupixent strength (Investing.com)
Apr-24-26 10:45AM	Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings (Pharmaceutical Technology)
03:04AM	Sanofi SA (SNY) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Developments (GuruFocus.com)
Apr-23-26 07:02AM	Sanofi posts upbeat sales as R&D pressure builds (BioPharma Dive)
06:34AM	Sanofi receives FDA approval for Tzield in paediatric diabetes (Pharmaceutical Business Review)
03:48AM	Sanofi climbs as strong Dupixent sales drive Q1 revenue and profit beat (Investing.com)
Apr-07-26 01:36PM	Sanofis bispecific scores in respiratory diseases but fails in eczema (Clinical Trials Arena)
04:34AM	Sanofi immune drug hopeful posts mixed results in mid-stage tests (BioPharma Dive)
Mar-30-26 05:31AM	Sanofi eczema drug weighed down by mixed results, safety concerns (BioPharma Dive)
Mar-27-26 07:56AM	AstraZeneca lung drug gets surprise win in COPD trials (BioPharma Dive)
Mar-24-26 06:36AM	Kali and Sanofi sign licence agreement for KT501 autoimmune disease antibody (Pharmaceutical Business Review)
Mar-23-26 08:15AM	Earendil Labs lands $787m to fund biologics development push (Pharmaceutical Technology)
08:15AM	Apogee strengthens case for longer-lasting eczema drug (BioPharma Dive)
06:16AM	FDA seeks feedback on voucher program; Study data lift overhang on Insmed shares (BioPharma Dive)
Mar-20-26 09:13AM	Earendil Labs, an AI-powered drugmaker, hauls in $787M (BioPharma Dive)
Mar-17-26 02:32PM	Transient but transformative: Sanofis mRNA CAR-T enters in vivo race (Pharmaceutical Technology)
Mar-12-26 11:08PM	Vaxart Inc (VXRT) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ... (GuruFocus.com)
03:33AM	Poolbeg Pharma adds CAR-T therapy expert to scientific advisory board (Proactive)
Mar-09-26 08:31PM	Analyst Report: Sanofi (Morningstar Research)
12:07PM	Dianthus Therapeutics Has Appreciated 13-Fold Over Two Years. What's Going On? (Investor's Business Daily)
09:35AM	Will Weak Gardasil Sales Continue to Weigh on MRK's Top Line in 2026? (Zacks)
09:22AM	Dianthus Therapeutics Stock Rallies-Rare Disease Study Success Fuels Optimism (Benzinga)
Mar-06-26 02:33AM	Germanys Merck KGaA Expects Currency Headwinds to Weigh on Earnings (The Wall Street Journal)
Mar-05-26 08:02PM	Euroapi SA (EAPIF) Full Year 2025 Earnings Call Highlights: Strong EBITDA Growth Amid Sales ... (GuruFocus.com)
02:11PM	Podcast: Sanofis head of clinical supply chain operations on evolving the clinical trial supply model (Clinical Trials Arena)
Mar-04-26 02:02PM	Sanofi bets on Sino Biopharms transplant drug in $1.5bn licensing deal (Pharmaceutical Technology)
06:57AM	Blackstone puts $400M into Teva, Sanofi gut disease drug (BioPharma Dive)
Mar-03-26 10:50AM	Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EU (Zacks)
10:00AM	Sanofi's Wayrilz Gets Orphan Drug Tag for IgG4-Related Disease in Japan (Zacks)
04:46AM	Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Sanofi and Bayer (Zacks)
Mar-02-26 09:10AM	REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in Urticaria (Zacks)
08:39AM	4 Large-Cap Pharma Stocks to Watch as Industry Recovery Gains Steam (Zacks)
08:16AM	Roche Multiple Sclerosis Drug Meets Main Goal in Late-Stage Trial (The Wall Street Journal)
07:49AM	MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot (Zacks)
05:59AM	Sanofi receives CHMP recommendation for Dupixent approval in Europe (Pharmaceutical Business Review)
Mar-01-26 04:26AM	Sanofi (SNY) and Regeneron's Dupixent Recommended for EU Approval (Insider Monkey)
Feb-28-26 01:32PM	Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029 (MarketBeat)
Feb-27-26 02:20PM	What's Going On With Novavax Stock On Friday? (Benzinga)
09:34AM	Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway (Zacks)

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

CEO & DirectorMs. Belen Garijo Lopez M.D.

Executive VP & CFOMr. Francois-Xavier Roger

Chief Scientific Officer & Head of ResearchDr. Michael Quigley Ph.D.

Head of Investor Relations & General MedicinesMr. Thomas Kudsk Larsen

Executive VP & General CounselMs. Jamie Haney

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sanofi	10% Owner	Aug 06 '26	Buy	17.00	300,000	5,100,000	1,082,855	Aug 07 03:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SNY

Sanofi ADR

Upgrade your Finviz experience